NextGen Healthcare Launches NextGen® Gastro Suite to Enhance GI Care
NextGen Healthcare Launches NextGen® Gastro Suite to Enhance GI Care NextGen Healthcare, a leader in healthcare technology innovation, has introduced the NextGen® Gastro Suite, a new solution designed to integrate gastroenterology-specific workflows into the NextGen® Enterprise EHR (electronic health record).…
Inflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy
Inflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy Inflammasome Therapeutics, a clinical-stage biotech company at the forefront of developing dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative diseases, has announced promising topline results from a clinical trial…
Sinaptica Launches Co-Development of SinaptiStim® for Alzheimer’s, Pivotal Trial Set for 2025
Sinaptica Launches Co-Development of SinaptiStim® for Alzheimer’s, Pivotal Trial Set for 2025 Sinaptica Therapeutics, Inc., a clinical-stage company at the forefront of developing personalized neuromodulation treatments for Alzheimer’s and other neurodegenerative diseases, has announced the initiation of co-development for the…
Medidata Expands Leadership to Drive Patient-Centered Innovation
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions for the life sciences industry, has announced new appointments to its leadership team. Alicia Staley has been named Chief Patient Officer and Senior Vice President of Social Impact…
SurGenTec Gains FDA Clearance for OsteoFlo® HydroFiber™ for Stand-Alone Use
SurGenTec Gains FDA Clearance for OsteoFlo® HydroFiber™ for Stand-Alone Use SurGenTec is excited to announce that its innovative product, OsteoFlo HydroFiber, has received FDA 510(k) clearance, marking a major milestone in the evolution of bone graft technology. This clearance establishes…
Belle Expands In-Home and Virtual Care for 50M+ Polychronic Medicare Members
Belle Expands In-Home and Virtual Care for 50M+ Polychronic Medicare Members Leveraging insights from over a quarter of a million in-home visits with medically complex individuals, Belle has expanded its successful model for providing home-based, proactive chronic care management. Belle…
Cancer Research Accelerated: Guardant Health and ConcertAI Launch Data-As-A-Service
Cancer Research Accelerated: Guardant Health and ConcertAI Launch Data-As-A-Service Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, and ConcertAI, a top provider of oncology real-world evidence (RWD) data and AI-driven SaaS technology, have announced a new collaboration. This…
Neurodegenerative Disease Imaging and Biomarkers: Enigma and UW-Madison Partner
Neurodegenerative Disease Imaging and Biomarkers: Enigma and UW-Madison Partner Enigma Biomedical USA, Inc. (Enigma) and the University of Wisconsin–Madison (UW–Madison) have announced a new partnership aimed at advancing the development of next-generation Positron Emission Tomography (PET) imaging and fluid biomarkers…
Massive Bio Recognized by White House Cancer Moonshot, Launches $15M Initiative at JPM 2025
Massive Bio Recognized by White House Cancer Moonshot, Launches $15M Initiative at JPM 2025 Massive Bio is proud to announce its inclusion in the White House Office of Science & Technology Policy’s upcoming Cancer Moonshot Fact Sheet, highlighting its innovative…
Reports Positive Results from RESTORE Trial of ReActiv8® by Mainstay Medical
Reports Positive Results from RESTORE Trial of ReActiv8® by Mainstay Medical Mainstay Medical Holdings plc reports today the publication of positive one-year results from the RESTORE randomized clinical trial of ReActiv8®, a treatment for intractable chronic low back pain. The…
Zai Lab Reports Positive TIVDAK Results in China for Cervical Cancer
Zai Lab Reports Positive TIVDAK Results in China for Cervical Cancer Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating that TIVDAK (tisotumab vedotin)…
GenSight Biologics Announces Groundbreaking 5-Year Outcomes for Unilateral LUMEVOQ® Gene Therapy
GenSight Biologics Announces Groundbreaking 5-Year Outcomes for Unilateral LUMEVOQ® Gene Therapy GenSight Biologics (Euronext: SIGHT) has announced the publication of five-year follow-up data for patients treated with its investigational gene therapy, LUMEVOQ® (lenadogene nolparvovec), for Leber Hereditary Optic Neuropathy (LHON).…